BioCaptiva has Developed the BioCollector, a Medical Device that Captures cfDNA

Prototype testing shows that the device has the potential to greatly enhance detection of early-stage cancers in patients without the need for surgical biopsy. It could also pave the way for new approaches to disease monitoring, resulting in better outcomes for patients.

The BioCollector works alongside a standard apheresis machine, filtering cfDNA from the patient’s blood system. It captures cfDNA (circulating free DNA) in much greater quantities than the current standard of a single blood draw. It can therefore overcome a significant current limitation of cancer liquid biopsy testing.

BioCaptiva is a spin-out from The University of Edinburgh. The device is based on a decade of research led by Professor Tim Aitman, Director of the Centre for Genomic and Experimental Medicine, and Professor Mark Bradley of the University’s School of Chemistry. Both researchers are co-founders and directors of the new company.

The company has received seed investment to facilitate its first trials to prove its safe use in humans. Should the technology prove successful, BioCaptiva plans to scale up its technology ahead of regulatory clinical trials, scheduled for completion during 2024.

A recent report estimates that the global liquid biopsy market could be worth more than $6 billion by 2025.

YEAR OF INVESTMENT
2021
WEBSITE
BioCaptiva.com
OBSERVER
Sarah Hardy